Validated Laboratory Standard
Revision 1 · Lyophilized Solid Powder
Dual GIP / GLP-1 Incretin Receptor Co-Agonist Analytical Titration Standard. Formulated for in-vitro research and laboratory analytical validation.
Dual GIP / GLP-1 Incretin Receptor Co-Agonist Analytical Titration Standard. Formulated for in-vitro research and laboratory analytical validation.
What it is: Tirzepatide is a synthetic 39-amino-acid peptide that represents a major scientific breakthrough: a first-in-class dual agonist that activates both GIP and GLP-1 receptors simultaneously.
How it works: By triggering both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, Tirzepatide coordinates metabolic control on two fronts. GIP enhances fat cell sensitivity and lipid metabolism, while GLP-1 curbs appetite and controls blood sugar. Together, they create a synergistic effect on fat loss and metabolic rate that surpasses single-hormone compounds.
Why researchers study it: Studied for massive body weight and fat reduction (averaging 20–25% in clinical trials), reversal of type 2 diabetes, fatty liver resolution, sleep apnea improvement, and cardiovascular risk reduction.
Biochemical Basis of Biased GIP Signaling, Pancreatic Beta-Cell Preservation, and Head-to-Head Comparative SURPASS Trial Evidence.
Tirzepatide (molecular formula C225H348N48O68, molecular weight 4813.45 Da) is a 39-amino acid synthetic peptide whose sequence is based on native human GIP(1-39). The sequence contains four strategic amino acid substitutions that fundamentally alter enzymatic stability and receptor selectivity: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys({AEEA}2-gamma-Glu-C20-diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-{Aib}-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
The primary modifications include: (1) replacement of Ala2 with 2-aminoisobutyric acid (Aib2) to block N-terminal cleavage by DPP-4; (2) substitution of Ile13 with Aib13 to enhance stability and optimize secondary helical packing; (3) conjugation of a C20 diacid fatty acyl chain at the epsilon-amine of Lys20 through a bis-AEEA-gamma-Glu linker; and (4) a C-terminal 11-residue extension identical to the C-terminal tail of exendin-4 (residues 29-39), which stabilizes tertiary solution structure and promotes favorable receptor contact.
The C20 dicarboxylic acid side-chain binds with high affinity to bovine and human serum albumin. In contrast to single fatty acids, the dicarboxylate moiety presents dual polar interactions at the albumin Sudlow site, yielding steady-state plasma binding >99% and extending the mean in vivo elimination half-life to approximately 120 hours (5 days) in humans.
Tirzepatide exhibits distinctive imbalanced affinity and biased intracellular signaling across its two target receptors. In vitro human receptor binding studies confirm that tirzepatide binds the human GIPR with a Ki of 0.135 nM (comparable to native GIP at 0.108 nM), whereas its affinity for the human GLP-1R is approximately 5-fold weaker (Ki 4.2 nM vs 0.85 nM for native GLP-1).
Despite its lower binding affinity for the GLP-1R, tirzepatide stimulates full-agonist maximal efficacy (Emax) in generating intracellular cAMP. More remarkably, when examining downstream receptor fate, Willard et al. (JCI Insight 2020) demonstrated that tirzepatide is a 'biased' GIPR agonist: it generates equivalent cAMP levels to native GIP but exhibits an 80% reduction in beta-arrestin-2 recruitment.
Because beta-arrestin-2 mediates receptor internalization and endosomal trafficking to lysosomal degradation pathways, tirzepatide's biased signaling prevents rapid receptor depletion from the cell membrane. This prolonged surface residence time allows sustained signal transduction even in states of chronic pharmacological receptor occupancy.
In isolated pancreatic islet perifusion studies, tirzepatide restores both first-phase and second-phase glucose-dependent insulin secretion in diabetic rodent and human donor islets. This insulinotropic effect operates synergistically: GIPR stimulation amplifies intracellular calcium entry, while GLP-1R enhances calcium sensitivity of secretory vesicle exocytosis.
Beyond acute secretagogue actions, tirzepatide confers robust cytoprotective benefits on beta-cell mass. Under glucolipotoxic stress, tirzepatide treatment downregulates markers of endoplasmic reticulum (ER) stress—suppressing C/EBP homologous protein (CHOP) and phosphorylated protein kinase RNA-like ER kinase (p-PERK)—and elevates anti-apoptotic Bcl-2 expression, significantly attenuating apoptosis.
In peripheral white adipose tissue, GIPR stimulation by tirzepatide exerts distinct temporal actions: in postprandial states with elevated insulin, GIP promotes lipid buffer storage into subcutaneous depots (preventing ectopic visceral and hepatic fat accumulation); during fasting or caloric restriction, it sensitizes adipocyte hormone-sensitive lipase (HSL) to catecholamines, accelerating systemic lipid mobilization.
Tirzepatide's clinical efficacy was validated through the extensive global SURPASS (type 2 diabetes) and SURMOUNT (obesity) Phase 3 registration trial programs. In the landmark SURPASS-2 trial (Frías et al., NEJM 2021), 1,879 patients were randomized to receive once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) versus semaglutide 1.0 mg. At week 40, mean HbA1c reductions were -2.01%, -2.24%, and -2.30% for tirzepatide compared to -1.86% for semaglutide 1.0 mg (p < 0.001 for all comparisons).
Body weight reductions were substantially greater with tirzepatide: -7.6 kg (5 mg), -9.3 kg (10 mg), and -11.2 kg (15 mg) versus -5.7 kg for semaglutide 1.0 mg. Furthermore, in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) in 2,539 adults with obesity or overweight without diabetes, the 15 mg dose of tirzepatide produced a mean weight reduction of 20.9% (-23.6 kg) at 72 weeks, with 63% of participants achieving a ≥20% reduction.
In addition to weight and glycemic endpoints, tirzepatide elicited substantial reductions in circulating triglycerides (down 24-31%), VLDL, and fasting insulin, while elevating HDL cholesterol by 7-11%, substantiating comprehensive cardiometabolic risk reduction.
In analytical and laboratory settings, tirzepatide is supplied as a lyophilized white crystalline cake. Reconstitution calculation: for a standard 10.0 mg vial, the addition of 2.0 mL of Bacteriostatic Water USP (0.9% benzyl alcohol) yields a working solution of 5.0 mg/mL (5,000 mcg/mL). Using a standard U-100 syringe (where 100 units = 1.0 mL, 1 unit = 0.01 mL = 50 mcg net tirzepatide): a 2.5 mg research dose corresponds precisely to 50 units (0.50 mL); a 5.0 mg dose corresponds to 100 units (1.0 mL).
Solvation requires gentle circumferential introduction of solvent along the glass shoulder of the vial. Inversion should be slow and steady; vigorous mechanical agitation must be strictly avoided to prevent disruption of the C20 diacid-peptide interface and secondary structure denaturation. The reconstituted solution is colorless, with an absorbance <0.010 at 450 nm and a pH between 6.5 and 7.5.
Lyophilized solid vials exhibit stable shelf-life at -20°C for up to 36 months. Reconstituted aqueous solutions stored under sterile conditions at 2°C–8°C retain ≥99.0% chromatographic purity for 28 days. Exposure to direct sunlight or ambient room temperature exceeding 25°C accelerates hydrolytic deamidation at Asn residues and must be avoided.
The safety and tolerability profile of tirzepatide is dominated by dose-dependent gastrointestinal side effects typical of the incretin class. In Phase 3 programs, nausea was reported in 12–18% of subjects, diarrhea in 12–17%, and vomiting in 6–10% at the 5 mg starting dose, rising to 22–33% for nausea at the 15 mg dose.
Crucially, the majority of GI symptoms are mild to moderate in severity, clustering predominantly during initial dose-escalation periods and declining rapidly during maintenance phases. Implementing a conservative 4-week step-wise titration schedule (2.5 mg for 4 weeks, escalating by 2.5 mg increments every 4 weeks) reduces GI-related discontinuation rates to below 5%.
Hypoglycemia incidence is negligible in non-diabetic populations because tirzepatide-mediated insulin release is strictly dependent on ambient plasma glucose concentrations (>5.0 mmol/L). Pancreatitis incidence in clinical trials was 0.2%, comparable to active comparator cohorts. As with all GLP-1 receptor-containing peptides, tirzepatide carries a class warning regarding thyroid C-cell tumors based on rodent bioassays, though human calcitonin levels demonstrated no clinically significant alterations.
Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution. Solution must be free of particulate matter before withdrawal. Never shake the vial after adding diluent; swirl smoothly and keep refrigerated between 2°C–8°C.
Diluent Ratio
2 mL per 10 mg (5 mg/mL)
Introduce 2.0 mL diluent slowly down the glass wall. The lyophilized matrix hydrates spontaneously within 60 seconds. Swirl gently in horizontal circles. Avoid shaking to prevent peptide foaming or denaturing.
Lyophilized Storage
-20°C in dark desiccator (shelf-life: 24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days for maximum stability
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~120 Hours (~5 Days terminal half-life)
Typical protocol duration: 12 to 20 Weeks progressive titration block; Washout: 4 to 6 Weeks between trial series
| Standard Compound Mass | 10 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 5.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 50.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution. Solution must be free of particulate matter before withdrawal. Never shake the vial after adding diluent; swirl smoothly and keep refrigerated between 2°C–8°C. |
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (10mg / 2.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 50.0 Units(0.50 mL) | Once weekly (Q7D) | |
| Weeks 5 to 8 | 5.0 mg | 100.0 Units(1.00 mL) | Once weekly (Q7D) | |
| Weeks 9 to 12 | 7.5 mg | 150.0 Units(1.50 mL) | Once weekly (Q7D) | |
| Weeks 13 to 16 | 10.0 mg | 200.0 Units(2.00 mL) | Once weekly (Q7D) | |
| Weeks 17+ | 15.0 mg | 300.0 Units(3.00 mL) | Once weekly (Q7D) |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 2.50 mg (Weeks 1–4 Initiation) | 0.50 mL | 50 Units 50.0 units (0.50 mL) on U-100 syringe |
| 5.00 mg (Weeks 5–8 Escalation) | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 2.50 mg (Weeks 1–4 Initiation) | 0.5 mL (500 µL) | 50 Units | 50.0 units (0.50 mL) on U-100 syringe |
| 5.00 mg (Weeks 5–8 Escalation) | 1 mL (1000 µL) | 100 Units | 100.0 units (1.00 mL) on U-100 syringe |
| Vial Net Mass | BAC Water | Concentration | 2.5 mg Dose | 5.0 mg Dose | 7.5 mg Dose | 10.0 mg Dose | Recommended Phase |
|---|---|---|---|---|---|---|---|
| 10 mg Vial | 2.0 mL | 5.0 mg/mL | 50 units (0.50 mL) | 100 units (1.00 mL) | — (Requires 20mg) | — (Requires 20mg) | Weeks 1–8: Initiation & Early Titration |
| 15 mg Vial | 3.0 mL | 5.0 mg/mL | 50 units (0.50 mL) | 100 units (1.00 mL) | 150 units (1.50 mL) | — | Extended low-dose or intermediate titration |
| 20 mg Vial | 2.0 mL | 10.0 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 75 units (0.75 mL) | 100 units (1.00 mL) | Weeks 9+: High-Dose Escalation |
| 30 mg Vial | 3.0 mL | 10.0 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 75 units (0.75 mL) | 100 units (1.00 mL) | Weeks 13+: High-Dose Maintenance |
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 50 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units) | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✕ Exceeded by 20 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 50 units |
| 1 mL (100 Units)BEST FIT | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 50 units |
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for Tirzepatide.
Do NOT reconstitute all 7 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Weeks 1 to 4 | 2.5 mg | 50 Units(0.50 mL) | Vial #1(7.5mg rem) | 2.5 mg / 60.0 mg |
| Week 2 | Weeks 1 to 4 | 2.5 mg | 50 Units(0.50 mL) | Vial #1(5mg rem) | 5.0 mg / 60.0 mg |
| Week 3 | Weeks 1 to 4 | 2.5 mg | 50 Units(0.50 mL) | Vial #1(2.5mg rem) | 7.5 mg / 60.0 mg |
| Week 4 | Weeks 1 to 4 | 2.5 mg | 50 Units(0.50 mL) | Vial #1(0mg rem) | 10.0 mg / 60.0 mg |
| Week 5 | Weeks 5 to 8 | 5.0 mg | 100 Units(1.00 mL) | Vial #2(5mg rem) | 15.0 mg / 60.0 mg |
| Week 6 | Weeks 5 to 8 | 5.0 mg | 100 Units(1.00 mL) | Vial #2(0mg rem) | 20.0 mg / 60.0 mg |
| Week 7 | Weeks 5 to 8 | 5.0 mg | 100 Units(1.00 mL) | Vial #3(5mg rem) | 25.0 mg / 60.0 mg |
| Week 8 | Weeks 5 to 8 | 5.0 mg | 100 Units(1.00 mL) | Vial #3(0mg rem) | 30.0 mg / 60.0 mg |
| Week 9 | Weeks 9 to 12 | 7.5 mg | 150 Units(1.50 mL) | Vial #4(2.5mg rem) | 37.5 mg / 60.0 mg |
| Week 10 | Weeks 9 to 12 | 7.5 mg | 150 Units(1.50 mL) | Vial #5(2.5mg rem) | 45.0 mg / 60.0 mg |
| Week 11 | Weeks 9 to 12 | 7.5 mg | 150 Units(1.50 mL) | Vial #6(2.5mg rem) | 52.5 mg / 60.0 mg |
| Week 12 | Weeks 9 to 12 | 7.5 mg | 150 Units(1.50 mL) | Vial #7(2.5mg rem) | 60.0 mg / 60.0 mg |
Study duration: 12 to 20 Weeks progressive titration block · Washout: 4 to 6 Weeks between trial series
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–4Starting Baseline | 2.5 mg | 1x Every 7 Days | Phase 1: Titration Initiation: Receptor acclimatization, GIP lipid buffering, and gastrointestinal tolerance calibration (50.0 units (0.50 mL) on U-100 syringe at 5.0 mg/mL concentration) |
| Weeks 5–8 | 5 mg | 1x Every 7 Days | Phase 2: Primary Response Escalation: Adipose thermogenesis, uncoupling protein-1 (UCP-1) stimulation, and insulin sensitivity enhancement (100.0 units (1.00 mL) on U-100 syringe) |
| Weeks 9–12 | 7.5 mg | 1x Every 7 Days | Phase 3: Advanced Metabolic Assays: Maximum dual-receptor synergy and continuous hepatic triglyceride clearance (Requires higher concentration vial (15mg or 20mg) or 1.50 mL volume) |
| Weeks 13+ | 10 mg | 1x Every 7 Days | Phase 4: Ceiling Efficacy Window: Ceiling efficacy assays in intensive metabolic research models (10.0 mg protocol target ceiling) |
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for Tirzepatide
Operating Window: +2°C to +8°C (36°F to 46°F)
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
Introduce 2.0 mL diluent slowly down the glass wall. The lyophilized matrix hydrates spontaneously within 60 seconds. Swirl gently in horizontal circles. Avoid shaking to prevent peptide foaming or denaturing.
Tirzepatide displays an estimated half-life of ~120 Hours (~5 Days terminal half-life). Typical study protocols run for 12 to 20 Weeks progressive titration block followed by a washout period of 4 to 6 Weeks between trial series.
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Standard Lyophilized Monograph
Dual GIP / GLP-1 Incretin Receptor Co-Agonist Analytical Titration Standard. Formulated for in-vitro research and laboratory analytical validation.
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 10 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.0 mL | 5.00 mg/mL | 1 Unit = 50.0 mcg (0.01 mL) |
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 2.5 mg | 50.0 Units (0.500 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 3.8 mg | 75.0 Units (0.750 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 2.5 mg | 50.0 Units (0.500 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA